|Table of Contents|

Research progress of endocrine therapy in patients with ESR1 gene mutation in advanced breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 01
Page:
189-193
Research Field:
Publishing date:

Info

Title:
Research progress of endocrine therapy in patients with ESR1 gene mutation in advanced breast cancer
Author(s):
KONG Qichao1; WANG Fusheng2
1.The Second Clinical Medical College of Shanxi Medical University,Shanxi Taiyuan 030001,China;2.Department of Breast Surgery,Second Hospital of Shanxi Medical University,Shanxi Taiyuan 030001,China.
Keywords:
breast cancer; estrogen receptor; endocrine therapy; aromatase inhibitor; CDK4/6 inhibitor
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.01.036
Abstract:
The most common molecular type of breast cancer is the lumen subtype,which expresses estrogen receptor(ER) and progesterone receptor(PR) and is generally treated with surgery and supplemental endocrine therapy(ET).Major treatments of breast cancer include estrogen deprivation and the use of selective estrogen modulators or anticoagulants,which have shown efficacy in the treatment of early and advanced diseases.Estrogen receptor 1(ESR1) gene mutations that are not ligand dependent are a common mechanism of resistance to endocrine therapy during aromatase inhibitor(AI) therapy for advanced estrogen receptor positive(ER+) breast cancer.Clinical studies have shown that ESR1 mutations can occur in primary tumors and increase in the frequency of mutations during advanced breast cancer metastasis,mostly following aromatase inhibitor endocrine therapy.Recent studies have explored the role of ESR1 mutations as a potential prognostic and predictive biomarker for breast cancer,suggesting that ESR1 mutations may be associated with further aggressiveness of breast cancer.The development of targeted therapy for ESR1 gene mutation is an important exploration for advanced breast cancer.This paper mainly expounds the adaptive mechanism of endocrine resistance,and focuses on how ESR1 mutation can provide information for new treatment,so as to improve the future clinical efficacy of breast cancer.

References:

［1］REINERT T,GONCALVES R,BINES J.Implications of ESR1 mutations in hormone receptor-positive breast cancer［J］.Curr Treat Options Oncol,2018,19(5):24.
［2］MA CX,REINERT T,CHMIELEWSKA I,et al.Mechanisms of aromatase inhibitor resistance［J］.Nat Rev Cancer,2015,15(5):261-275.
［3］JESELSOHN R,BUCHWALTER G,DE ANGELIS C,et al.ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer［J］.Nat Rev Clin Oncol,2015,12(10):573-583.
［4］HUANG B,WARNER M,GUSTAFSSON JA.Estrogen receptors in breast carcinogenesis and endocrine therapy［J］.Mol Cell Endocrinol,2015,73(8):256.
［5］OSBORNE CK,SCHIFF R.Mechanisms of endocrine resistance in breast cancer［J］.Annu Rev Med,2011,62:233-247.
［6］SCHIFF R,MASSARWEH SA,SHOU J,et al.Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance［J］.Clin Cancer Res,2004,10(1):331-336.
［7］SCHIFF R,MASSARWEH SA,SHOU J,et al.Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance:Implicated role of growth factor signaling and estrogen receptor coregulators［J］.Cancer Chemother Pharmacol,2005,56(1):10-20.
［8］REINERT T,BARRIOS CH.Optimal management of hormone receptor positive metastatic breast cancer in 2016［J］.Ther Adv Med Oncol,2015,7(6):304-320.
［9］RAZAVI P,CHANG MT,XU G,et al.The genomic landscape of endocrine-resistant advanced breast cancers［J］.Cancer Cell,2018,34(3):427-438.
［10］JORDAN VC,O'MALLEY BW.Selective estrogen-receptor modulators and antihormonal resistance in breast cancer［J］.J Clin Oncol,2007,25(36):5815-5824.
［11］WEIS KE,EKENA K,THOMAS JA,et al.Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein［J］.Mol Endocrinol,1996,10(11):1388-1398.
［12］ZHANG QX,BORG A,WOLF DM,et al.An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer［J］.Cancer Res,1997,57(7):1244-1249.
［13］REINERT T,SAAD ED,BARRIOS CH,et al.Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer［J］.Front Oncol,2017,7:26.
［14］The Cancer Genome Atlas Network.Comprehensive molecular portraits of human breast tumours［J］.Nature,2012,490:61-70.
［15］KARNIK PS,KULKARNI S,LIU XP,et al.Estrogen receptor mutations in tamoxifen-resistant breast cancer［J］.Cancer Res,1994,54(2):349-353.
［16］ROODI N,BAILEY LR,KAO WY,et al.Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer［J］.J Natl Cancer Inst,1995,87(6):446-451.
［17］JESELSOHN R,YELENSKY R,BUCHWALTER G,et al.Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer［J］.Clin Cancer Res,2014,20(7):1757-1767.
［18］DUSTIN D,GU G,FUQUA SAW.ESR1 mutations in breast cancer［J］.Cancer,2019,125(21):3714-3728.
［19］WANG P,BAHREINI A,GYANCHANDANI R,et al.Sensitive detection of mono-and polyclonal ESR1 mutations in primary tumors,metastatic lesions,and cell-free DNA of breast cancer patients［J］.Clin Cancer Res,2016,22(5):1130-1137.
［20］NAJIM O,SEGHERS S,SERGOYNNE L,et al.The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer:A systematic review and meta-analysis of randomized and non-randomized trials［J］.Biochim Biophys Acta Rev Cancer,2019,1872(2):188315.
［21］CARDOSO F,COSTA A,NORTON L,et al.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer(ABC2)［J］.Breast,2014,23(5):489-502.
［22］CARDOSO F,PALUCH-SHIMON S,SENKUS E,et al.5th ESO-ESMO international consensus guidelines for advanced breast cancer(ABC 5)［J］.Ann Oncol,2020,31(12):1623-1649.
［23］COLE MP,JONES CT,TODD ID.A new anti-oestrogenic agent in late breast cancer.An early clinical appraisal of ICI46474［J］.Br J Cancer,1971,25(2):270-275.
［24］ALLOUCHERY V,BEAUSSIRE L,PERDRIX A,et al.Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients［J］.Breast Cancer Res,2018,20(1):40.
［25］KUANG Y,SIDDIQUI B,HU J,et al.Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer［J］.NPJ Breast Cancer,2018,4:22.
［26］DE SANTO I,MCCARTNEY A,MIGLIACCIO I,et al.The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy［J］.Cancers(Basel),2019,11(12):1894.
［27］JOHNSTON SR,KILBURN LS,ELLIS P,et al.Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer(SoFEA):A composite,multicentre,phase 3 randomised trial［J］.Lancet Oncol,2013,14:989-998.
［28］JM SPOERKE,S GENDREAU,K WALTER,et al.Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant［J］.Nat Commun,2016,7:11579.
［29］DI LEO A,JERUSALEM G,PETRUZELKA L,et al.Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer［J］.J Clin Oncol,2010,28(30):4594-4600.
［30］DI LEO A,JERUSALEM G,PETRUZELKA L,et al.Final overall survival:Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial［J］.J Natl Cancer Inst,2014,106(1):djt337.
［31］ROBERTSON JFR,BONDARENKO IM,TRISHKINA E,et al.Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer(FALCON):An international,randomised,double-blind,phase 3 trial［J］.Lancet,2016,388(10063):2997-3005.
［32］CRUZ M,REINERT T,CRISTOFANILLI M.Emerging innovative therapeutic approaches leveraging cyclin-dependent kinase inhibitors to treat advanced breast cancer［J］.Clin Pharmacol Ther,2018,103(6):1009-1019.
［33］GOETZ MP,TOI M,CAMPONE M,et al.MONARCH 3:Abemaciclib as initial therapy for advanced breast cancer［J］.J Clin Oncol,2017,35(32):3638-3646.
［34］ZHANG P,ZHANG Q,TONG Z,et al.Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive,HER2-negative advanced breast cancer(DAWNA-2):A multicentre,randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2023,24(6):646-657.
［35］ALVAREZ-FERNANDEZ M,MALUMBRES M.Mechanisms of sensitivity and resistance to CDK4/6 inhibition［J］.Cancer Cell,2020,37(4):514-529.
［36］HORTOBAGYI GN,STEMMER SM,BURRIS HA,et al.Ribociclib as first-line therapy for HR-positive,advanced breast cancer［J］.N Engl J Med,2016,375(18):1738-1748.
［37］SLAMON DJ,NEVEN P,CHIA S,et al.Overall survival with ribociclib plus fulvestrant in advanced breast cancer［J］.N Engl J Med,2020,382(6):514-524.
［38］TURNER NC,SLAMON DJ,RO J,et al.Overall survival with palbociclib and fulvestrant in advanced breast cancer［J］.N Engl J Med,2018,379(20):1926-1936.
［39］CRISTOFANILLI M,TURNER NC,BONDARENKO I,et al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive,HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3):Final analysis of the multicentre,double-blind,phase 3 randomised controlled trial［J］.Lancet Oncol,2016,17(4):425-439.
［40］BACHELOT T,BOURGIER C,CROPET C,et al.Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive,human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors:A GINECO study［J］.J Clin Oncol,2012,30(22):2718-2724.

Memo

Memo:
-
Last Update: 2023-11-30